Joshua Tobias, PhD: Construction of recombinant vaccine strains over-expressing protective bacterial Antigens
Mittwoch, 4. September 2013, 12.00 s.t.
Institut für Spezifische Prophylaxe und Tropenmedizin, Kinderspitalgasse 15, Hörsaal 1
COLLOQUIUM IN PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY
Joshua Tobias, PhD – Dept. Microbiology and Immunology, University of Gothenburg
Joshua Tobias, since January 2008, is a molecular biologist researcher in the department of Microbiology and Immunology and Gothenburg University Vaccine Research Center (GUVAX), at the institute of Biomedicine, University of Gothenburg, Sweden. He did his postdoctoral research in the same institute between 2004 and 2007. His research during these two periods has included both basic and advanced research on different gastrointestinal pathogens, mainly eneterotoxigenic E. coli (ETEC) and Helicobacter pylori. His advanced work on ETEC resulted in several recombinant strains with the potential of being used as whole-cell killed oral candidate vaccine strains against ETEC in human. One of these strains has been recently tested in a Phase-I clinical trial, in Sweden. Based on the promising results of this clinical trial, an additional Phase-I clinical trial is now ongoing to test a full and the 2nd generation of an ETEC vaccine, including several recombinant strains which Joshua has been directly involved in their construction. Since he has started his postdoc, Joshua’s work has resulted in 4 patents, close to 15 original research articles, and two reviews. Joshua is directly involved in organizing departmental seminars, and he is also the representative of the young researchers in the department. Joshua has a degree of Bachelor of Science in Biology, and Master of Science and PhD degrees in Microbiology, from Tel-Aviv University.
Venue: Institute of Specific Prophylaxis and Tropical Medicine, lecture hall 1
Time: Wednesday, September 4th, 2013, 12.00 s.t.
Host: Ursula Wiedermann
CENTRE FOR PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY MEDICAL UNIVERSITY
zurück zu: CePII